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ABSTRACT:
The neurotoxic side effects observed for the neuroleptic agent
haloperidol have been associated with its pyridinium metabolite. In
a previous study, a silicon analog of haloperidol (sila-haloperidol)
was synthesized, which contains a silicon atom instead of the
carbon atom in the 4-position of the piperidine ring. In the present
study, the phase I metabolism of sila-haloperidol and haloperidol
was studied in rat and human liver microsomes. The phase II
metabolism was studied in rat, dog, and human hepatocytes and
also in liver microsomes supplemented with UDP-glucuronic acid
(UDPGA). A major metabolite of haloperidol, the pyridinium metab-
olite, was not formed in the microsomal incubations with sila-
haloperidol. For sila-haloperidol, three metabolites originating
from opening of the piperidine ring were observed, a mechanism
that has not been observed for haloperidol. One of the significant
phase II metabolites of haloperidol was the glucuronide of the
hydroxy group bound to the piperidine ring. For sila-haloperidol,
the analogous metabolite was not observed in the hepatocytes or
in the liver microsomal incubations containing UDPGA. If silanol
(SiOH) groups are not glucuronidated, introducing silanol groups in
drug molecules could provide an opportunity to enhance the hy-
drophilicity without allowing for direct phase II metabolism. To
provide further support for the observed differences in metabolic
pathways between haloperidol and sila-haloperidol, the metabo-
lism of another pair of C/Si analogs was studied, namely, trifluperi-
dol and sila-trifluperidol. These studies showed the same differ-
ences in metabolic pathways as between sila-haloperidol and
haloperidol.
Haloperidol was developed in the late 1950s and was found to be a
potent neuroleptic agent (Janssen et al., 1959). Haloperidol is a
dopamine (D2) receptor antagonist and is still used in the treatment of
schizophrenia, although it may cause severe extrapyramidal side ef-
fects, including parkinsonism and tardive dyskinesia (Levinson, 1991;
Casey, 1995). The pyridinium metabolite of haloperidol has been
proposed to contribute to these neurotoxic side effects because it
structurally resembles 1-methyl-4-phenylpyridinium (commonly re-
ferred to as MMP), an inducer of Parkinson disease-like symptoms
(Subramanyam et al., 1991a; Dauer and Przedborski, 2003).
In the search for analogs of haloperidol, a silicon analog (sila-
haloperidol) was synthesized, where the quaternary R3COH carbon
atom in the piperidine ring was replaced by a silicon atom (R3SiOH).
The synthesis and the physicochemical and pharmacological proper-
ties of sila-haloperidol have been reported previously (Tacke et al.,
2004a, 2008). As a minor part of an extensive study of sila-haloper-
idol, including synthesis and pharmacological properties, three major
phase I metabolites in human liver microsomes (HLMs) were tenta-
tively identified. One of these metabolites was proposed to be formed
via N-dealkylation and the other two by opening of the piperidine ring
(Tacke et al., 2008). The present study will focus on a thorough
investigation of both phase I and II metabolism of sila-haloperidol
compared with those of haloperidol.
The use of organosilicon chemistry in drug design has been re-
viewed previously (Tacke and Linoh, 1989; Bains and Tacke, 2003;
Showell and Mills, 2003; Mills and Showell, 2004; Pooni and Show-
ell, 2006; Gately and West, 2007). Carbon and silicon both are group
14 elements and are similar in that they form four covalent bonds with
many other elements. However, there are also striking differences.
Silicon (1.17 Å) has a larger covalent radius than carbon (0.77 Å),
resulting in the formation of longer bonds and, therefore, in an
increase of the size of the sila-analog and its conformational flexibil-
ity. In addition, in general, an increased lipophilicity is observed for
silicon compounds compared with their corresponding carbon ana-
logs. Silicon (1.74, Allred-Rochow scale) is less electronegative than
carbon (2.50), leading to different polarizations of analogous carbon-
and silicon-element bonds, manifested by, for example, an increased
acidity of silanols compared with the analogous carbinols. These and
other sila-replacement effects may affect the chemical and physico-
chemical properties and may also alter the biological properties. For
example, altered bond lengths and angles may change the mole-
cule’s interaction with a receptor and hence the pharmacological
selectivity and/or potency. Replacing a carbon by a silicon atom
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may increase the potency of a compound if the carbinol serves as
a hydrogen bond donor within the pharmacophore because a silanol
is a better hydrogen bond donor than the corresponding carbinol
(Bains and Tacke, 2003; Showell and Mills, 2003; Mills and
Showell, 2004; Pooni and Showell, 2006).
Silicon switches of marketed drugs have recently been reviewed
(Pooni and Showell, 2006). The term carbon/silicon switch, also
called sila-substitution, is used when a silicon analog of a known drug
is synthesized where one carbon atom is replaced by a silicon atom,
leaving the rest of the structure unchanged. Examples of silicon
switches are (besides sila-haloperidol) sila-venlafaxine, sila-fexofena-
dine, and disila-bexarotene, studied in different in vitro systems
(Pooni and Showell, 2006).
Venlafaxine is an antidepressant that blocks the reuptake of sero-
tonin and noradrenaline. Venlafaxine and its silicon analog sila-
venlafaxine displayed similar physicochemical properties but differ-
ent pharmacological selectivity profiles (Daiss et al., 2006).
Fexofenadine is a histaminic H1 receptor antagonist used in the
treatment of allergies. The sila analog of fexofenadine was synthe-
sized to compare the pharmacological properties. Fexofenadine and
sila-fexofenadine displayed similar receptor profiles when tested
against a panel of histamine receptors (Tacke et al., 2004b). Bexaro-
tene is used in the treatment of cutaneous T-cell lymphoma and is a
retinoid X receptor-selective agonist. The disila analog (2-fold sila-
substitution) was synthesized to test the hypothesis that introducing
silicon in the drug molecule would change the molecular shape,
lipophilicity, and electrostatic potential to alter the pharmacodynamic
profile. Disila-bexarotene was shown to be an equally potent retinoid
X receptor agonist as the carbon analog (Daiss et al., 2005).
The aim of this study was to investigate the phase I and phase II
metabolism of sila-haloperidol compared with that of haloperidol and
to test the hypothesis that replacement of the quaternary R3COH
carbon atom of haloperidol by a silicon atom may potentially change
the metabolic pathways, for example, the pathway leading to the
potential neurotoxic pyridinium metabolite (Tacke et al., 2004a). In
addition, the aim was to provide a thorough metabolic investigation of
a silicon-containing compound studied in different in vitro systems.
In addition to the metabolism studies of haloperidol and sila-
haloperidol, another pair of structurally related carbon/silicon analogs
was investigated, namely, trifluperidol and sila-trifluperidol. Struc-
tures of the test compounds used in this study are shown in Fig. 1.
Materials and Methods
Chemicals. -NADPH (reduced form tetrasodium salt), leucine enkephalin
acetate hydrate, trifluperidol, Williams’ E medium without phenol red, 5,5-
diethyl-1,3-diphenyl-2-iminobarbituric acid, UDP-glucuronic acid (UDPGA)
trisodium salt, and water-free dimethyl sulfoxide were purchased from Sigma-
Aldrich (St. Louis, MO). Methanol was purchased from Rathburn Chemicals
(Walkerburn, Scotland, UK). Formic acid, ammonium acetate, and ammonia
solution (25% in water) were purchased from Merck (Darmstadt, Germany).
Acetonitrile and haloperidol were purchased from Thermo Fisher Scientific
(Waltham, MA). Gibco HEPES buffer solution (1 M), Gibco 10 Hanks’
balanced salt solution, and Gibco L-glutamine (200 mM) were purchased from
Invitrogen (Carlsbad, CA). Percoll separating solution (1.124 g/ml) was pur-
chased from VWR International (West Chester, PA). Brij-58 was purchased
from Fluka Chemie AG (Buchs, Switzerland). All of the solvents were of
analytical grade, and the water used in the experiments was obtained from a
water purification system (Elgastat Maxima; Elga Process Water/Veolia Water
Solutions & Technologies, Lane End, Buckinghamshire, UK). Sila-haloperi-
dol, sila-trifluperidol, and a synthetic reference compound of the N-dealkylated
metabolite of sila-haloperidol were synthesized as their hydrochlorides (Popp,
2008; Nguyen, 2009). Synthetic reference compounds of reduced haloperidol
(the secondary alcohol), the pyridinium ion metabolite, and N-oxide 1 of
haloperidol were donated by Professor Neal Castagnoli, Jr. (Subramanyam et
al., 1991b).
Liquid Chromatography/Mass Spectrometry Method. The samples were
analyzed by liquid chromatography (LC) [Waters ACQUITY ultraperformance
LC (UPLC), Milford, MA] on a Waters ACQUITY UPLC bridged ethyl hybrid
(C18 2.1  50 mm, 1.7 m) column at a flow rate of 750 l/min (the column
temperature was set at 40°C). Mobile phase A consisted of 5% acetonitrile and
0.1% formic acid in water, and mobile phase B was 100% acetonitrile. At the
start of the gradient, the acetonitrile content was 1% and was linearly increased
to 50% over 5 min. The acetonitrile content was then increased to 90% within
0.01 min. This condition was held for 0.69 min, and finally the initial mobile
phase composition was restored within 0.01 min. The UPLC system was
coupled to a Waters quadrupole/time-of-flight Premier instrument equipped
with an electrospray ionization source. Leucine-enkephalin was used as the
lock mass (m/z 556.2771) for accurate mass calibration and introduced using
the lock spray interface at 20 l/min (500 pg/l). Unless stated elsewhere,
samples were diluted 1:2 in mobile phase A, and aliquots of 5 l were injected
into the LC/mass spectrometry (MS) system. Full-scan spectra were acquired
in the positive ionization mode. For acquisition of tandem MS spectra, the
injection volume was 20 l, and generally a collision energy ramp (10–30 eV)
was used. The software programs used to process the data were MassLynx
(version 4.1) and MetaboLynx (Waters). The mass-to-charge ratios (m/z) of all
the relevant ions in the MS mode were determined within 5 ppm from the exact
mass of the proposed structure.
Liver Microsomal Incubations. HLMs were purchased from BD Bio-
sciences (San Jose, CA). The rat liver microsomes (RLMs) were purchased
from CellzDirect/Invitrogen (Carlsbad, CA). In addition to being characterized
by the manufacturers, the enzyme activities of the microsomes were confirmed
against a panel of common substrates and in-house compounds. The incubation
mixtures, containing 1.0 mg/ml liver microsomal protein and 10 M substrate
in 0.1 M phosphate buffer, pH 7.4, were preincubated for 5 min at 37°C. The
reaction was initiated by adding NADPH at a final concentration of 1 mM, and
the reaction mixtures were incubated for 60 min at 37°C. Control incubations
were conducted in the absence of NADPH and in the absence of substrate. The
reactions were quenched with an equal volume of ice-cold acetonitrile. The
samples were vortexed for 10 s and then centrifuged for 10 min at 4°C, 4000
rpm (2750g).
For the liver microsomal incubations with UDPGA, the incubation mix-
tures, containing 1.0 mg/ml liver microsomal protein (HLM or RLM), 0.5
mg/ml Brij-58, and 100 M substrate in 0.1 M phosphate buffer, pH 7.4, were
preincubated for 5 min at 37°C. The reaction was initiated by adding UDPGA
at a final concentration of 3 mM, and the reaction mixtures were incubated for
0 or 60 min at 37°C. The reactions were quenched with two parts ice-cold
acetonitrile. The samples were vortexed for 10 s and then centrifuged for 20
FIG. 1. Structures of the test compounds.
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min at 4°C, 4000 rpm (2750g). The supernatants were diluted 1:5 with water
before analysis.
Hepatocyte Incubations. Human (mixed male/female), dog (female), and
rat (female) cryopreserved hepatocytes were purchased from Celsius In Vitro
Technologies (Baltimore, MA). In addition to being characterized by the
manufacturers, the enzyme activities of the hepatocytes were confirmed
against a panel of common substrates and in-house substances. Metabolite
profiling was conducted using pooled cryopreserved animal hepatocytes at a
substrate concentration of 4 M. Substrate stock solutions of 10 mM were
prepared in dimethyl sulfoxide. The hepatocytes were quickly thawed in a
water bath kept at 37°C and transferred to 50-ml Falcon tubes (BD Bio-
sciences) containing prewarmed hepatocyte incubation medium. The hepato-
cyte incubation medium consisted of 2 mM L-glutamine, 25 mM HEPES,
diluted with Williams’ E medium to 500 ml, and the pH was set to 7.4. After
centrifugation (100g at 25°C for 6 min), the supernatant was removed, and the
pellet was resuspended in Percoll. After centrifugation (100g at 25°C for 20
min) the pellet was resuspended in hepatocyte incubation medium. The cells
were counted using the trypan blue exclusion method. After dilution to a
concentration of 2 million cells/ml in hepatocyte incubation medium, the
hepatocyte suspension was added to each well (25 l/well) of a 96-well plate.
The plate was placed in the incubator (Galaxy R CO2 Incubator; RS Biotech
Laboratory Equipment Ltd., Irvine, Scotland, UK) to preincubate for 10 min,
and the reaction was initiated by adding the prewarmed substrate solution (25
l of 8 M substrate solution/well). Blanks without substrate were also
prepared. For the time 0 time point, the hepatocyte incubations were first
treated with the quenching solution before the addition of substrate solution.
The incubations were stopped after 120 min by adding 3 volumes of ice-cold
stop solution: acetonitrile containing 0.8% formic acid and a volume marker (1
M 5,5-diethyl-1,3-diphenyl-2-iminobarbituric acid). The plates were kept at
20°C for at least 20 min and then centrifuged at 2750g at 4°C for 20 min. The
supernatants were diluted 1:1 with water, and the plates were kept at 20°C
until analysis.
Metabolite Nomenclature. This is a metabolism study of four different
compounds, and the intention was to highlight the similarities in the metabolic
pathways of these test compounds, as well as the differences. Thus, we have
chosen a metabolite nomenclature system that describes the metabolic path-
ways from which the metabolites originate. In cases where more than one
metabolite originates from the same metabolic pathway, the metabolites are
named based on their retention times, for example, OH1 elutes before OH2.
Results
In the present study, the phase I and II metabolism of haloperidol
was examined to compare the metabolic pathways with those of
sila-haloperidol. Relative metabolite amounts of the fraction metabo-
lized of haloperidol, estimated from integration of extracted ion chro-
matograms, are shown in Table 1. The cross-species metabolite
scheme obtained from microsomal and hepatocyte incubations of
haloperidol is shown in Fig. 2. The pyridinium metabolite was iden-
tified as a major metabolite in the microsomal incubations. Other
metabolites formed were tentatively assigned as two separate hy-
droxylated products (OH1 and OH2), two diasteromeric N-oxides
(N-oxide1 and N-oxide2), reduced haloperidol (red), and an N-deal-
kylated metabolite (N-dealk). The pyridinium ion metabolite, reduced
haloperidol, and the first eluting N-oxide diastereomer (N-oxide1)
were identified using synthetic reference compounds.
The major metabolites in hepatocytes were tentatively assigned to
be reduced haloperidol, the N-dealkylated metabolite, the pyridinium
metabolite, and a direct glucuronidation metabolite (Gluc). The direct
glucuronidation metabolite (glucuronidation of hydroxy group bound
to the piperidine ring) was formed by rat and human hepatocytes but
was not observed in dog hepatocytes. In humans the direct glucu-
ronidation metabolite of haloperidol has been shown to be a major
metabolite (Oida et al., 1989; Someya et al., 1992), and direct glucu-
ronidation is also a major metabolic pathway in rats (Miyazaki et al.,
1986). Minor metabolites in the hepatocytes were tentatively assigned
as hydroxylations, N-oxides and another, earlier eluting, glucuronida-
tion metabolite (OHGluc). No product ion spectrum of this latter
metabolite was obtained, but because the mass corresponds to a
hydroxylation and a glucuronidation, these reactions may occur in the
same or two separate positions of the molecule. Also in the hepatocyte
incubations, the pyridinium ion metabolite, reduced haloperidol, and
the first eluting N-oxide diastereomer (N-oxide1) were identified
using the synthetic reference compounds.
The reduction of the carbonyl function of haloperidol to a second-
ary alcohol was observed in rat, dog, and human hepatocytes. The
reduction was also observed in RLMs and HLMs but to a much
smaller extent. Carbonyl reduction in liver microsomes has been
reported previously (Beulz-Riche et al., 2001). It should be noted that
estimation of the amounts of reduced metabolites formed in liver
microsomes may be difficult because the metabolites may be subject
to redox cycling.
Incubations with RLMs and HLMs containing UDPGA, the cofac-
tor necessary for glucuronidation, were performed. The direct glucu-
ronidation metabolite of haloperidol was observed also in these incu-
bations. Extracted ion chromatograms of the direct glucuronidation
metabolites from the liver microsomal incubations with UDPGA are
included in the supplemental data. Because haloperidol and its major
metabolites are well characterized by MS and synthetic standard
compounds (Fang et al., 1992; Gorrod and Fang, 1993; Narayanan et
TABLE 1
Relative metabolite amounts of the fraction metabolized of haloperidol
Liver microsomes incubated for 60 min and hepatocytes incubated for 120 min. Data estimated from integration of extracted ion chromatograms.
Haloperidol
Metabolite m/z tR (min) RLM HLM Rat Heps Dog Heps Human Heps
Relative proportions of metabolites after incubation of haloperidol for 60/120 min (%)
N-Dealk 212 1.06 7 9 32 37 5
OHGluc 568 1.43 N.D. N.D. 2 0 0
Gluc 552 1.62 N.D. N.D. 10 0 17
OH1 392 1.71 3 2 1 0 0
OH2 392 1.78 3 1 1 0 0
Red 378 1.84 9 2 12 40 46
N-Oxide1 392 2.08 1 1 1 0 1
Pyridinium 354 2.18 73 83 39 14 31
N-Oxide2 392 2.23 4 1 4 9 0
Fraction of parent drug remaining after incubation (%)
Haloperidol 376 1.97 55 59 77 81 86
Heps, hepatocytes; N.D., not determined (no addition of UDPGA in this experiment).
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al., 2004), product ion spectra were not included in the supplemental
data.
Relative quantities of formed metabolites and remaining sila-haloperidol
in microsomal and hepatocyte incubations, estimated from integration of
extracted ion chromatograms, are summarized in Table 2. The cross-
species metabolite scheme obtained from microsomal and hepatocyte
incubations of sila-haloperidol is shown in Fig. 3. The product ion
spectra and proposed fragmentation pathways of sila-haloperidol me-
tabolites are shown in the supplemental data.
The metabolism of sila-haloperidol in RLMs and HLMs differs
from that of haloperidol. No sila-pyridinium metabolite was formed in
the liver microsomes for sila-haloperidol. Instead, two ring-opened
metabolites with [MH] ions at m/z 364 and 382, respectively, were
formed (ring-opened1 and ring-opened2). These two metabolites were
the major metabolites in the HLMs, whereas other metabolites were
tentatively assigned to be the N-dealkylated metabolite (N-dealk),
hydroxylation product of ring-opened1 (ring-opened1OH), reduced
sila-haloperidol (red), and a hydroxylated metabolite (OH). In the
RLMs, the hydroxylated and the N-dealkylated metabolites were the
major metabolites, whereas minor metabolites were tentatively as-
signed as reduced sila-haloperidol, the two ring-opened metabolites,
and the hydroxylation product of ring-opened1. The structure of the
N-dealkylated metabolite of sila-haloperidol was confirmed by com-
paring the retention time and the product ion spectrum with those of
the synthetic reference compound, whereas the proposed structures for
the other metabolites of sila-haloperidol are tentative assignments
based on interpretation of product ion spectra.
The fragment ions of sila-haloperidol and its metabolites are shown
in Table 3. The product ion spectrum of sila-haloperidol, shown in
Fig. 4, revealed three major fragment ions at m/z 165, 164, and 123.
These three fragment ions all originate from the left side of the
molecule and include the fluorophenyl group as shown by the pro-
posed fragmentation pathways in Fig. 5. The proposed fragments for
sila-haloperidol were used for tentative identification of the metabo-
FIG. 2. Proposed overall metabolism of haloperidol in HLMs, RLMs, and hepatocytes (HH, human; DH, dog; RH, rat).
TABLE 2
Relative metabolite amounts of the fraction metabolized of sila-haloperidol
Liver microsomes incubated for 60 min and hepatocytes incubated for 120 min. Data estimated from integration of extracted ion chromatograms.
Sila-haloperidol
Metabolite m/z tR (min) RLM HLM Rat Heps Dog Heps Human Heps
Relative proportions of metabolites after incubation of sila-haloperidol for 60/120 min (%)
N-Dealk 228 1.22 21 11 44 5 12
Ring-opened1OH 380 1.28 2 2 0 0 0
OHGluc 584 1.52 N.D. N.D. 39 0 0
Ring-opened1 364 1.74 4 63 0 10 25
OHSulfate 488 1.82 N.D. N.D. 3 0 0
OH 408 1.90 71 3 5 0 0
Ring-opened2 382 1.94 1 20 0 2 7
Red 394 2.01 1 1 9 84 56
Fraction of parent drug remaining after incubation (%)
Sila-haloperidol 392 2.18 83 65 80 61 94
Heps, hepatocytes; N.D., not determined (no addition of UDPGA in this experiment).
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lites of sila-haloperidol. For example, an addition of 16 Da to the
fragment at m/z 123 in the product ion spectrum of a metabolite
indicates a hydroxylation on the fluorophenyl moiety. Following the
same line of reasoning, the presence of the fragment at m/z 165
indicates that the left side of the molecule is intact and that the
modification has occurred somewhere in the remaining part of the
molecule.
One metabolite (OH) with a [MH] ion at m/z 408, correspond-
ing to an addition of 16 Da to sila-haloperidol, was observed in the
incubations with RLMs, HLMs, and rat hepatocytes. As this metab-
olite eluted earlier than sila-haloperidol in the chromatogram, it was
tentatively assigned as a hydroxylated rather than an N-oxygenated
metabolite. The pKa of the protonated amine is significantly higher
than that of the corresponding N-oxide. Thus, under the acidic con-
ditions used, the N-oxide is assumed to behave as being more li-
pophilic, whereas the hydroxylated metabolite would be expected to
behave as more polar than the parent compound, based on their
chromatographic retention times. Based on the product ion spectrum
(shown in the supplemental data), it is proposed that the hydroxylation
occurs on the chlorophenyl ring of sila-haloperidol. The presence of
the fragments at m/z 165, 164, and 123 in the product ion spectrum
indicates that the left side of the molecule is unchanged. A hydroxy-
lation on the piperidine ring would most likely give a major fragment
corresponding to the loss of water in the product ion spectrum (Ra-
manathan et al., 2000). The absence of such a fragment suggests the
chlorophenyl moiety of sila-haloperidol as the most likely site for the
hydroxylation.
The first eluting ring-opened metabolite gave a [MH] ion at m/z
364 and behaved as being more polar than the parent compound and
the ring-opened2 metabolite, based on their chromatographic retention
times as shown in Table 2. The product ion spectrum of the ring-
opened1 metabolite, shown in Fig. 6, revealed two major fragment
ions at m/z 172 and 164. The proposed fragmentation pathways of this
metabolite are shown in Fig. 7. A neutral loss of chlorophenyl vinyl
silanediol (200 Da) from m/z 364 is proposed to give the fragment ion
at m/z 164, which is also a major fragment ion in the product ion
spectrum of sila-haloperidol. A neutral loss of fluorophenyl dihydro-
pyrrole (163 Da) and ethene (28 Da) from m/z 364 is proposed to give
FIG. 3. Proposed overall metabolism of sila-haloperidol in HLMs, RLMs, and hepatocytes (HH, human; DH, dog; RH, rat).
TABLE 3
Sila-haloperidol and metabolites–fragmentation ions
Metabolite tR (min) MH
 m/z Major Product Ions m/z
N-Dealk 1.22 228.0608 190.0103, 192.0023, 172.0007, 173.9888
Ring-opened1OH 1.28 380.0875 380.0869, 382.0974, 188.9782, 190.9616, 164.0897
OHGluc 1.52 564.1508 584.1495, 586.1488, 408.1197, 410.1167, 165.0723, 164.0868
Ring-opened1 1.74 364.0931 364.0929, 366.0962, 172.9830, 174.9805, 164.0888
OHSulfate 1.82 488.0763 408.1190, 165.0749, 164.0860, 123.0249
OH 1.90 408.1191 408.1189, 410.1153, 165.0714, 164.0877, 123.0277
Ring-opened2 1.94 382.1031 382.0978, 172.9830, 174.9806, 165.0711, 164.0943, 123.0249
Red 2.01 394.1405 394.1395, 396.1375, 376.1292, 378.1279, 320.0648, 322.0673, 172.9824, 174.9797, 109.0477
Sila-haloperidol 2.18 392.1238 392.1243, 394.1137, 165.0698, 164.0886, 123.0283
77IN VITRO METABOLISM OF HALOPERIDOL AND SILA-HALOPERIDOL
FIG. 4. Product ion spectrum of sila-haloperidol.
FIG. 5. Proposed fragmentation pathways of sila-haloperidol.
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the fragment ion at m/z 172, retaining the chlorine atom. The absence
of the fragment ions at m/z 165 and 123 implies that the carbonyl
group is not present in the metabolite.
The second eluting ring-opened metabolite with a [MH] ion at
m/z 382 behaved as being more polar than the parent compound and
less polar than the ring-opened metabolite 1, based on their chromato-
graphic retention times as shown in Table 2. The proposed structure
of the ring-opened metabolite 2 is given in Fig. 3. The product ion
spectrum is given in the supplemental data along with a proposed
fragmentation pathway.
The metabolite with a [MH] ion at m/z 380 (ring-opened1OH)
corresponds to an addition of 16 Da to the ring-opened1 metabolite 1.
In the product ion spectrum, the fragment ion at m/z 172 was replaced
by a fragment ion at m/z 188. Consequently, this metabolite was
tentatively assigned as being hydroxylated on the chlorophenyl sub-
stituent (Fig. 3).
Sila-haloperidol was also incubated with rat, dog, and human
hepatocytes. Reduced sila-haloperidol was the major metabolite in the
dog and human hepatocytes, whereas the N-dealkylated metabolite
and a metabolite originating from hydroxylation and glucuronidation
(OHGluc) were the major metabolites in rat hepatocytes.
Two metabolites, with [MH] ions at m/z 488 and 584, respec-
tively, appeared in the rat hepatocyte incubations but not in dog and
human hepatocyte incubations. The metabolite with a [MH] ion at
m/z 488 corresponds to an addition of 96 Da to sila-haloperidol,
corresponding to a hydroxylation and a sulfate conjugation
(OHSulfate). The product ion spectrum displayed an initial loss of
80 Da to form the fragment ion at m/z 408. Because no loss of water
is seen from the fragment at m/z 408, the hydroxylation does not likely
occur on an aliphatic carbon atom. Because the fragments at m/z 165
FIG. 6. The product ion spectrum of the ring-opened1 metabolite of sila-haloperidol.
FIG. 7. Proposed fragmentation pathways of the ring-opened1 metabolite of sila-
haloperidol.
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and 123 are retained, the left side of the molecule is unchanged. Hence
the most likely route of formation for this metabolite is hydroxylation
on the chlorophenyl moiety followed by a sulfate conjugation of that
hydroxyl group, as proposed in Fig. 3.
The metabolite with a [MH] ion at m/z 584 corresponds to an
addition of 192 Da to sila-haloperidol, corresponding to a hydroxy-
lation and glucuronide conjugation. Except for an initial neutral loss
of 176 Da instead of 80 Da, the product ion spectrum of m/z 584 is
very similar to that of m/z 488 (OHSulfate). Hence the most likely
route of formation for this metabolite is hydroxylation on the chloro-
phenyl moiety followed by a glucuronide conjugation of that hydroxyl
group, as proposed in Fig. 3.
Noteworthy is that the hydroxylated metabolite of sila-haloperidol
was the major metabolite in the RLMs, whereas it was a minor
metabolite in the rat hepatocytes, as illustrated in Table 2. Presum-
ably, this metabolite was further metabolized by glucuronide conju-
gation and also sulfate conjugation. Any metabolite resulting from a
direct glucuronidation of the SiOH group was not observed for sila-
haloperidol. In the incubations with activated RLMs and HLMs sup-
plemented with UDPGA, no direct glucuronidation of the SiOH group
of sila-haloperidol was observed.
The identified metabolites were well separated using the liquid
chromatographic method developed for these studies. Extracted ion
chromatograms of the metabolites of haloperidol and sila-haloperidol,
after incubation with human hepatocytes, are shown in Fig. 8. Sila-
haloperidol is more lipophilic than haloperidol, and this is manifested
by a shift in retention times of approximately 0.2 min. N-Dealkylation
and reduction occurs for both analogs in human hepatocytes. The
differences in metabolism of the piperidine ring are obvious; haloper-
idol was metabolized to the pyridinium metabolite, and sila-haloper-
idol formed the two ring-opened metabolites. In addition, sila-halo-
peridol did not form the corresponding direct glucuronidation
metabolite observed for haloperidol.
It is clear that a substitution of the carbon atom in the 4-position of
the piperidine ring of haloperidol by a silicon atom resulted in sig-
nificant differences in the metabolic pathways of the molecule. To
provide further support for the observed differences, the metabolism
of another structurally related carbon/silicon pair was studied, namely,
trifluperidol and sila-trifluperidol, shown in Fig. 1. Like haloperidol,
trifluperidol is a neuroleptic agent that has been used in the treatment
of schizophrenia (Gallant et al., 1963). The distribution, metabolism,
and excretion of trifluperidol in the rat have been published previously
(Souijn et al., 1967; Lewi et al., 1970). The phase I metabolism of
trifluperidol and sila-trifluperidol was studied in RLMs and HLMs,
whereas the phase II metabolism was studied in rat and human
hepatocytes. In addition, liver microsomal incubations supplemented
with UDPGA were performed. In general, both the phase I and phase
II metabolism of trifluperidol/sila-trifluperidol were analogous to
those of haloperidol/sila-haloperidol. The corresponding metabolites
were observed for trifluperidol/sila-trifluperidol that were observed
for haloperidol/sila-haloperidol, as shown in Table 4. The product ion
spectra of trifluperidol and sila-trifluperidol, parent drugs and metab-
olites, are shown in the supplemental data.
Discussion
Replacement of the quaternary R3COH carbon atom of haloper-
idol by a silicon atom significantly altered its metabolic fate. For
haloperidol, the pyridinium metabolite is formed via dehydration
and oxidation of the piperidine ring to the pyridinium ion. For
sila-haloperidol, the analogous sila-pyridinium ion was not formed, and
new metabolic pathways originating from opening of the piperidine ring
were observed.
FIG. 8. Metabolism of haloperidol and sila-haloperidol, respectively, by human hepatocytes. Extracted ion chromatograms of m/z 212, 552, 378, 392, and 354 for
haloperidol and m/z 228, 364, 382, and 394 for sila-haloperidol. The retention times of haloperidol and sila-haloperidol are marked in the different chromatograms.
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Two pathways have been proposed for the formation of the halo-
peridol pyridinium metabolite. The first pathway is initiated by -car-
bon ( to the nitrogen) hydroxylation followed by water elimination
to yield the iminum ion that directly or via its enamine conjugate base
is converted to a dihydropyridinium intermediate. The second path-
way is initiated by dehydration to yield a tetrahydropyridine interme-
diate that then undergoes -carbon hydroxylation to yield the dihy-
dropyridinium intermediate. The dihydropyridinium ion is then
proposed to being spontaneously oxidized to the pyridinium ion
(Subramanyam et al., 1991b).
Whereas carbon tends to form stable double and triple bonds with
itself and other analogous atoms, double or triple bonds with silicon
atoms are generally thermodynamically unstable under physiological
conditions (Brook, 2000). The thermodynamic instability and reactiv-
ity of the SiC double bond, together with the fact that the silicon-
oxygen bond is strong, explain why the silicon-oxygen bond in
sila-haloperidol does not break to eliminate water and yield the SiC
bond, which is required for the formation of a sila-pyridinium metab-
olite.
By analogy to the pathway leading to the pyridinium metabolite of
haloperidol, the metabolism of the piperidine ring of sila-haloperidol
is most likely initiated by a hydroxylation at the -carbon ( to the
nitrogen), followed by a ring opening to form an intermediate with an
aldehyde and a secondary amine functionality. This intermediate, an
-silyl aldehyde, is very reactive and easily undergoes hydrolytic
cleavage of the Si-C bond (Larson, 1996). The proposed cyclization
following the elimination of acetaldehyde is outlined in Fig. 9.
For the phase II metabolism, as revealed by the incubations with
hepatocytes, the most striking difference between haloperidol and its
silicon analog is the difference in glucuronide formation. For halo-
peridol, the direct conjugation of the piperidine-bound hydroxyl group
with glucuronic acid resulted in a significant metabolite in rat and
human hepatocytes. The corresponding metabolite was not observed
for sila-haloperidol.
In the rat and human microsomal incubations with UDPGA,
glucuronidation was observed on the piperidine-bound hydroxyl
group of haloperidol but not on the SiOH group of sila-haloperidol.
A speculation would be that the direct glucuronidation of the
silanol (SiOH) group occurs, but that the resulting conjugate with
its hydrolytically sensitive Si-OC bond then undergoes hydrolysis
to give the corresponding silanol and free glucuronic acid. In this
context it is important to note that the chemical reactivity of
thermodynamically very stable (but against water kinetically la-
bile) Si-OC bond of alkoxysilanes (alkyl silyl ethers) differs sig-
nificantly compared with that of the C-OC bond of analogous
dialkyl ethers (Colvin, 1981; Osterholtz and Pohl, 1992). An
alternative explanation for the absence of glucuronidation in the
case of sila-haloperidol might be that the silanol is a poor substrate
for the UDP-glucuronosyltransferases. Further studies are neces-
sary to clarify this issue.
Decreased lipophilicity of drug molecules may be desirable
because it may improve drug metabolism, pharmacokinetics and
physicochemical properties, for example, increased solubility and
decreased hepatic clearance by cytochrome P450 (Smith, 2001). A
means to modify lipophilicity while retaining the major structural
properties of the molecule is to introduce hydroxyl groups. How-
ever, a common drawback of this strategy is high clearance orig-
inating from phase II metabolism, for example, glucuronidation.
Hence, if silanol (SiOH) groups do not form stable glucuronide
conjugates, this process would provide a possibility to introduce
hydrophilicity in drug molecules without allowing for direct phase
II metabolism. Although this is an attractive hypothesis favoring
silanol analogs of drug candidates, further evaluation is needed, for
example, more structurally diverse silanol-containing compounds
should be investigated. In addition, if an unstable glucuronide
actually is formed, studies on its potential reactivity toward bio-
logical nucleophiles must be considered.
Noteworthy is that the direct glucuronidation metabolite of
trifluperidol was only formed in small amounts by human hepato-
cytes and not by rat hepatocytes. For haloperidol, the correspond-
ing metabolite was observed in substantial amounts in both rat and
human hepatocyte incubations. The same differences were ob-
served in the rat and human microsomal incubations containing
UDPGA. This result might be explained by the fact that the
chlorine atom is in the para-position of the phenyl ring of halo-
peridol and the trifluoromethyl group is in the meta-position of the
TABLE 4
Relative metabolite amounts of the fraction metabolized of trifluperidol and sila-trifluperidol, respectively
Liver microsomes incubated for 60 min and hepatocytes incubated for 120 min. Data estimated from integration of extracted ion chromatograms.
Metabolite m/z tR (min) RLM HLM Rat Heps Human Heps
Trifluperidol: Relative proportions of metabolites after incubation of trifluperidol for 60/120 min (%)
N-Dealk 246 1.19 42 35 51 30
OHGluc 602 1.58 N.D. N.D. 1 0
Gluc 586 1.65 N.D. N.D. 0 1
OH1 426 1.81 3 1 0 0
OH2 426 1.86 3 2 1 1
Red 412 1.90 8 1 12 12
N-Oxide1 426 2.10 1 1 1 1
Pyridinium 388 2.17 43 60 35 55
N-Oxide2 426 2.23 1 1 1 1
Fraction of parent drug remaining after incubation (%)
Trifluperidol 410 2.03 59 34 50 67
Sila-trifluperidol: Relative proportions of metabolites after incubation of sila-trifluperidol for 60/120 min (%)
N-Dealk 262 1.32 55 40 34 41
Ring-opened1OH 414 1.59 15 0 0 0
OHGluc 618 1.65 N.D. N.D. 60 0
Ring-opened1 398 1.80 9 46 0 37
Ring-opened2 416 1.98 3 13 0 13
OH 442 2.01 18 1 6 0
Red 428 2.03 0 0 0 8
Fraction of parent drug remaining after incubation (%)
Sila-trifluperidol 426 2.18 21 62 56 79
Heps, hepatocytes; N.D., not determined (no addition of UDPGA in this experiment).
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phenyl ring of trifluperidol. Thus, the direct glucuronidation might
occur to a less extent for trifluperidol as a result of a larger steric
hindrance from the trifluoromethyl group in the meta-position.
Silicon analogs of known drugs might be interesting from sev-
eral points of view. Replacement of a carbon atom by a silicon
atom in a known drug changes the geometric and electronic prop-
erties and thereby the size, shape, conformational behavior, chem-
ical reactivity, and lipophilicity of the molecule. This effect might
in turn alter the interaction with a receptor and hence change the
pharmacodynamics of the drug. The metabolism of the drug may
change and therefore also metabolism-related toxicity. This study
has shown major differences in metabolic pathways between two
different pairs of carbon/silicon analogs. Another important issue
is that of intellectual property; silicon analogs of known drugs may
open up for a new type of drug development process. Because the
original carbon-based drug has been tested thoroughly, the corre-
sponding silicon analog may be able to shortcut the discovery part
of drug development. Some silicon-containing drugs are currently
being evaluated in clinical trials (Bains and Tacke, 2003; Gately
and West, 2007), and it will be interesting to follow the outcome
of those studies with respect to pharmacodynamic properties and
safety compared with the original molecule.
In conclusion, structures of three major phase I metabolites of
sila-haloperidol formed in HLMs were proposed in a previous
study (Tacke et al., 2008). The present study builds further on
those data in that a comprehensive comparison between the me-
tabolism of haloperidol and trifluperidol and their sila-analogs has
been performed in several in vitro systems, including liver micro-
somes from rats and humans with and without activation for
glucuronidation and hepatocytes from humans, rats, and dogs to
cover phase I and phase II metabolism. As a result, in addition to
the three metabolites of the previous study, at least five additional
phase I and phase II metabolites for each compound have been
characterized and mechanisms for their formation rationalized.
One major difference was the absence of the pyridinium ion
metabolite, a major metabolite for haloperidol and trifluperidol, in
the incubations with the silicon analogs. Instead, the piperidine
ring of both silicon analogs opens metabolically, and different ring
opening metabolites were observed. Another important difference
was that direct glucuronidation did not occur for sila-haloperidol as
it did for haloperidol. This difference was not as obvious for
trifluperidol and sila-trifluperidol possibly because the trifluorom-
ethyl group in the meta-position may hinder direct glucuronidation
for both compounds.
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